Guardian Pharmacy Services, Inc. (GRDN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GRDN SEC filings page.
Guardian Pharmacy Services, Inc. (GRDN) reported $1.4B in revenue for fiscal year 2025, up 17.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Guardian’s reported turnaround came from lower overhead converting sales growth into profit and cash, not from major gross-margin expansion.
Revenue expanded while gross margin stayed nearly flat; meanwhile, SG&A fell from$307M in FY2024 to$220M in FY2025. That combination makes the profit swing look primarily like a cost-structure change—through overhead reduction or operating leverage—rather than a materially richer revenue mix.
Operating cash flow of
Equity increased
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Guardian Pharmacy Services, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Guardian Pharmacy Services, Inc. has an operating margin of 5.0%, meaning the company retains $5 of operating profit per $100 of revenue. This below-average margin results in a low score of 27/100, suggesting thin profitability after operating expenses. This is up from -5.1% the prior year.
Guardian Pharmacy Services, Inc.'s revenue surged 17.9% year-over-year to $1.4B, reflecting rapid business expansion. This strong growth earns a score of 80/100.
Guardian Pharmacy Services, Inc. carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.
Guardian Pharmacy Services, Inc.'s current ratio of 1.38 indicates adequate short-term liquidity, earning a score of 37/100. The company can meet its near-term obligations, though with limited headroom.
Guardian Pharmacy Services, Inc. has a free cash flow margin of 6.0%, earning a moderate score of 45/100. The company generates positive cash flow after capital investments, but with room for improvement.
Guardian Pharmacy Services, Inc.'s ROE of 22.6% shows moderate profitability relative to equity, earning a score of 34/100. This is up from -73.4% the prior year.
Guardian Pharmacy Services, Inc. scores 12.54, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.6B) relative to total liabilities ($194.7M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Guardian Pharmacy Services, Inc. passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Guardian Pharmacy Services, Inc. generates $2.04 in operating cash flow ($100.3M OCF vs $49.2M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Guardian Pharmacy Services, Inc. earns $109.32 in operating income for every $1 of interest expense ($72.7M vs $665K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Guardian Pharmacy Services, Inc. generated $351.8M in revenue in Q2 2026. This represents an increase of 2.2% from the same quarter a year earlier. Against the prior quarter it is up 4.5%.
Guardian Pharmacy Services, Inc.'s EBITDA was $26.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 46.4% from the same quarter a year earlier. Against the prior quarter it is up 11.8%.
Guardian Pharmacy Services, Inc. reported $21.9M in net income in Q2 2026. This represents an increase of 142.2% from the same quarter a year earlier. Against the prior quarter it is up 64.5%.
Not reported for Q2 2026.
Cash & Balance Sheet
Guardian Pharmacy Services, Inc. held $89.8M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Guardian Pharmacy Services, Inc.'s gross margin was 22.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 3.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.1 percentage points.
Guardian Pharmacy Services, Inc.'s operating margin was 5.9% in Q2 2026, reflecting core business profitability. This is up 2.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.6 percentage points.
Guardian Pharmacy Services, Inc.'s net profit margin was 6.2% in Q2 2026, showing the share of revenue converted to profit. This is up 3.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.3 percentage points.
Guardian Pharmacy Services, Inc.'s ROE was 8.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 3.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.8 percentage points.
Capital Allocation
None of these metrics is reported for Q2 2026.
GRDN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $351.8M+2.2% | $336.6M+2.2% | $397.6M+17.4% | $377.4M+20.0% | $344.3M+14.8% | $329.3M+19.6% | $338.6M | $314.4M+19.7% |
| Cost of Revenue | $271.7M-1.6% | $260.3M-1.8% | $312.1M+15.0% | $302.7M+19.4% | $276.2M+15.7% | $265.0M+20.3% | $271.5M | $253.5M+20.4% |
| Gross Profit | $80.0M+17.5% | $76.3M+18.6% | $85.5M+27.4% | $74.7M+22.7% | $68.1M+11.2% | $64.3M+16.8% | $67.1M | $60.9M+16.6% |
| SG&A Expenses | $59.4M+6.9% | $58.6M+14.2% | $54.7M+8.7% | $58.4M-64.7% | $55.6M+25.5% | $51.3M+8.9% | $50.3M | $165.5M+182.8% |
| Operating Income | $20.6M+64.1% | $17.7M+35.9% | $30.8M+83.6% | $16.4M+115.6% | $12.6M-26.0% | $13.0M+63.9% | $16.8M | -$104.6M-1552.7% |
| EBITDA | $26.5M+46.4% | $23.7M+29.4% | $36.5M+66.6% | $22.2M+122.3% | $18.1M-17.4% | $18.3M+44.1% | $21.9M | -$99.6M |
| Interest Expense | $154K-10.5% | $154K-9.4% | $163K-61.3% | $160K-84.4% | $172K-83.9% | $170K-77.8% | $421K | $1.0M+43.3% |
| Income Tax | $7.7M+104.0% | $4.7M+23.9% | $9.8M+124.5% | $7.0M+3898.9% | $3.8M | $3.8M | $4.4M | $176K |
| Net Income | $21.9M+142.2% | $13.3M+40.7% | $20.9M+331.6% | $9.8M+108.0% | $9.0M | $9.4M+33.2% | $4.8M | -$122.0M-1644.0% |
Not reported in any period shown, so not listed: R&D Expenses, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
GRDN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $443.6M+24.5% | $426.9M+27.8% | $412.7M+28.6% | $390.0M+12.1% | $356.3M | $334.0M | $320.8M+18.3% | $348.0M |
| Current Assets | $254.7M+49.4% | $235.2M+41.6% | $221.6M+45.8% | $198.3M+10.0% | $170.5M | $166.0M | $152.0M+17.3% | $180.3M |
| Cash & Equivalents | $89.8M+377.3% | $64.9M+363.6% | $65.6M+1308.1% | $36.5M-2.0% | $18.8M+1123.5% | $14.0M+7945.4% | $4.7M+519.7% | $37.2M+5893.7% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $50.4M+14.2% | $47.2M+8.6% | $43.4M+6.9% | $47.9M+5.8% | $44.2M | $43.4M | $40.5M+10.4% | $45.2M |
| Accounts Receivable | $103.8M+10.2% | $111.7M+14.7% | $101.6M+4.6% | $106.2M+16.8% | $94.1M | $97.4M | $97.2M+25.7% | $90.9M |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $79.7M+4.7% | $79.7M+15.1% | $79.7M+15.1% | $79.6M+16.3% | $76.2M | $69.3M | $69.3M+23.6% | $68.4M |
| Total Liabilities | $185.9M+5.2% | $194.5M+13.9% | $194.7M+14.0% | $194.5M-9.1% | $176.7M | $170.8M | $170.8M-19.2% | $214.1M |
| Current Liabilities | $154.0M+7.0% | $160.5M+10.5% | $160.7M+11.5% | $161.9M+2.3% | $144.0M | $145.3M | $144.1M+4.4% | $158.3M |
| Non-Current Liabilities | $31.9M-2.4% | $34.0M+33.3% | $34.0M+27.4% | $32.6M-41.6% | $32.7M | $25.5M | $26.7M-63.6% | $55.8M |
| Long-Term Debt | N/A | N/A | $0 | N/A | N/A | N/A | $0-100.0% | $28.7M |
| Total Equity | $257.6M+43.4% | $232.4M+42.4% | $217.9M+45.3% | $195.5M+46.0% | $179.7M+214.0% | $163.2M+188.5% | $150.0M+150.5% | $133.9M+124.3% |
| Retained Earnings | $101.5M+185.1% | $79.6M+199.7% | $66.3M+287.4% | $45.4M+776.7% | $35.6M | $26.6M | $17.1M | $5.2M |
GRDN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $30.0M+50.6% | $6.1M-65.5% | $34.6M+54.9% | $28.2M+1401.7% | $19.9M-31.6% | $17.6M+102.8% | $22.3M | -$2.2M |
| Depreciation & Amortization | $5.8M+5.8% | $6.0M+13.5% | $5.7M+11.4% | $5.8M+16.9% | $5.5M+12.6% | $5.3M+10.9% | $5.2M | $5.0M |
| Stock-Based Compensation | N/A | $1.9M-53.1% | N/A | $4.4M-96.4% | $4.4M+1734.9% | $4.0M-33.3% | N/A | $122.4M |
| Capital Expenditures | N/A | N/A | $495K-78.0% | $4.0M+80.5% | N/A | N/A | $2.3M | $2.2M |
| Free Cash Flow | N/A | N/A | $34.1M+69.8% | $24.2M+651.7% | N/A | N/A | $20.1M | -$4.4M |
| Investing Cash Flow | -$4.3M+66.9% | -$4.8M+14.3% | -$4.7M+28.9% | -$9.0M-26.6% | -$13.0M+0.8% | -$5.5M-54.1% | -$6.6M | -$7.1M |
| Financing Cash Flow | -$805K+61.9% | -$2.0M+23.6% | -$758K+98.4% | -$1.5M-103.4% | -$2.1M+85.6% | -$2.7M+52.7% | -$48.3M | $44.9M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
GRDN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 22.8%+3.0pp | 22.7%+3.1pp | 21.5%+1.7pp | 19.8%+0.4pp | 19.8%-0.6pp | 19.5%-0.5pp | 19.8% | 19.4%-0.5pp |
| Operating Margin | 5.9%+2.2pp | 5.3%+1.3pp | 7.7%+2.8pp | 4.3%+37.6pp | 3.6%-2.0pp | 4.0%+1.1pp | 5.0% | -33.3%-30.9pp |
| Net Margin | 6.2%+3.6pp | 4.0%+1.1pp | 5.3%+3.8pp | 2.6%+41.4pp | 2.6%+2.6pp | 2.9%+0.3pp | 1.4% | -38.8%-36.1pp |
| Return on Equity | 8.5%+3.5pp | 5.7%-0.1pp | 9.6%+6.4pp | 5.0%+96.1pp | 5.0%+5.0pp | 5.8%-6.8pp | 3.2% | -91.1%-79.4pp |
| Return on Assets | 4.9%+2.4pp | 3.1%+0.3pp | 5.1%+3.6pp | 2.5%+37.6pp | 2.5% | 2.8% | 1.5% | -35.0% |
| Current Ratio | 1.65+0.5x | 1.46+0.3x | 1.38+0.3x | 1.22+0.1x | 1.18 | 1.14 | 1.05+0.1x | 1.14 |
| Debt-to-Equity | 0.72-0.3x | 0.84-0.2x | 0.000.0x | 1.00+0.8x | 0.98 | 1.05 | 0.00-0.3x | 0.21 |
| Asset Turnover | 0.79-0.2x | 0.79-0.2x | 0.96-0.1x | 0.97+0.1x | 0.97 | 0.99 | 1.06 | 0.90 |
| FCF Margin | N/A | N/A | 8.6%+2.7pp | 6.4%+7.8pp | N/A | N/A | 5.9% | -1.4% |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Guardian Pharmacy Services, Inc. GRDN | FY2025 | $1.4B | $49.2M | 3.4% | $2.6B | 53/100 |
| Ardent Health, Inc. ARDT | FY2025 | $6.3B | $135.8M | 2.1% | $1.5B | 28/100 |
| National Healthcare Corp. NHC | FY2025 | $1.5B | $120.0M | 7.9% | $3.6B | 67/100 |
| P3 Health Partners Inc. PIII | FY2025 | $1.5B | -$147.9M | -10.1% | $24.1M | 24/100 |
| Aveanna Healthcare Holdings Inc. AVAH | FY2026 | $2.4B | $225K | 0.0% | $2.7B | 36/100 |
| Brookdale Senior Living, Inc. BKD | FY2025 | $3.2B | -$262.7M | -8.2% | $2.5B | 25/100 |
Where Guardian Pharmacy Services, Inc. Ranks
Frequently Asked Questions
What is Guardian Pharmacy Services, Inc.'s annual revenue?
Guardian Pharmacy Services, Inc. (GRDN) reported $1.4B in total revenue for fiscal year 2025. This represents a 17.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Guardian Pharmacy Services, Inc.'s revenue growing?
Guardian Pharmacy Services, Inc. (GRDN) revenue grew by 17.9% year-over-year, from $1.2B to $1.4B in fiscal year 2025.
Is Guardian Pharmacy Services, Inc. profitable?
Yes, Guardian Pharmacy Services, Inc. (GRDN) reported a net income of $49.2M in fiscal year 2025, with a net profit margin of 3.4%.
What is Guardian Pharmacy Services, Inc.'s EBITDA?
Guardian Pharmacy Services, Inc. (GRDN) had EBITDA of $95.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Guardian Pharmacy Services, Inc. have?
As of fiscal year 2025, Guardian Pharmacy Services, Inc. (GRDN) had $65.6M in cash and equivalents against $0 in long-term debt.
What is Guardian Pharmacy Services, Inc.'s gross margin?
Guardian Pharmacy Services, Inc. (GRDN) had a gross margin of 20.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Guardian Pharmacy Services, Inc.'s operating margin?
Guardian Pharmacy Services, Inc. (GRDN) had an operating margin of 5.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Guardian Pharmacy Services, Inc.'s net profit margin?
Guardian Pharmacy Services, Inc. (GRDN) had a net profit margin of 3.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Guardian Pharmacy Services, Inc.'s return on equity (ROE)?
Guardian Pharmacy Services, Inc. (GRDN) has a return on equity of 22.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Guardian Pharmacy Services, Inc.'s free cash flow?
Guardian Pharmacy Services, Inc. (GRDN) generated $86.8M in free cash flow during fiscal year 2025. This represents a 100.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Guardian Pharmacy Services, Inc.'s operating cash flow?
Guardian Pharmacy Services, Inc. (GRDN) generated $100.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Guardian Pharmacy Services, Inc.'s total assets?
Guardian Pharmacy Services, Inc. (GRDN) had $412.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Guardian Pharmacy Services, Inc.'s capital expenditures?
Guardian Pharmacy Services, Inc. (GRDN) invested $13.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Guardian Pharmacy Services, Inc.'s current ratio?
Guardian Pharmacy Services, Inc. (GRDN) had a current ratio of 1.38 as of fiscal year 2025, which is considered adequate.
What is Guardian Pharmacy Services, Inc.'s debt-to-equity ratio?
Guardian Pharmacy Services, Inc. (GRDN) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Guardian Pharmacy Services, Inc.'s return on assets (ROA)?
Guardian Pharmacy Services, Inc. (GRDN) had a return on assets of 11.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Guardian Pharmacy Services, Inc.'s P/E ratio?
Guardian Pharmacy Services, Inc. (GRDN) trades at 39.6x earnings, its market capitalization divided by net income of $65.9M net income, trailing 12 months to June 30, 2026. The market capitalization is $2.6B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Guardian Pharmacy Services, Inc.'s price-to-sales ratio?
Guardian Pharmacy Services, Inc. (GRDN) trades at 1.8x sales, its market capitalization divided by revenue of $1.5B revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.6B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Guardian Pharmacy Services, Inc.'s Altman Z-Score?
Guardian Pharmacy Services, Inc. (GRDN) has an Altman Z-Score of 12.54, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Guardian Pharmacy Services, Inc.'s Piotroski F-Score?
Guardian Pharmacy Services, Inc. (GRDN) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Guardian Pharmacy Services, Inc.'s earnings high quality?
Guardian Pharmacy Services, Inc. (GRDN) has an earnings quality ratio of 2.04x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Guardian Pharmacy Services, Inc. cover its interest payments?
Guardian Pharmacy Services, Inc. (GRDN) has an interest coverage ratio of 109.32x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Guardian Pharmacy Services, Inc.?
Guardian Pharmacy Services, Inc. (GRDN) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.